Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jim Xiang

Showing results (11-20 of 169) with videos related to

Pageof 17
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2005
A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cellsJim Xiang, Hui Huang, Yongqing Liu
Methods in Molecular Medicine|June 22, 2005
Genetically engineered myeloma cell vaccineSiguo Hao, Tim Chan, Jim Xiang
Methods in Molecular Medicine|June 22, 2005
Dendritic cell/myeloma hybrid vaccineDajing Xia, Tim Chan, Jim Xiang
Journal of Leukocyte Biology|July 13, 2007
Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memorySiguo Hao, Jinying Yuan, Jim Xiang
Journal of Immunology (Baltimore, Md. : 1950)|August 22, 2006
CD8+ cytotoxic T-APC stimulate central memory CD8+ T cell responses via acquired peptide-MHC class I complexes and CD80 costimulation, and IL-2 secretionDajing Xia, Siguo Hao, Jim Xiang
Cancer Biotherapy & Radiopharmaceuticals|August 3, 2004
Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunityDajing Xia, Fang Li, Jim Xiang
Cancer Biotherapy & Radiopharmaceuticals|March 28, 2002
Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cellsYongqing Liu, Mabood Qureshi, Jim Xiang
Oncotargets and Therapy|November 10, 2018
Novel EXO-T vaccine using polyclonal CD4<sup>+</sup> T cells armed with HER2-specific exosomes for HER2-positive breast cancerRong Li, Rajni Chibbar, Jim Xiang
Breast Cancer (Tokyo, Japan)|January 31, 2015
HER2-directed therapy: current treatment options for HER2-positive breast cancerShahid Ahmed, Amer Sami, Jim Xiang
Immunotargets and Therapy|July 11, 2018
Multiple effects of CD40-CD40L axis in immunity against infection and cancerAnjuman Ara, Khawaja Ashfaque Ahmed, Jim Xiang
Pageof 17

Showing results (11-20 of 169) with videos related to

Sort By:
Pageof 17
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2005
A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cellsJim Xiang, Hui Huang, Yongqing Liu
Methods in Molecular Medicine|June 22, 2005
Genetically engineered myeloma cell vaccineSiguo Hao, Tim Chan, Jim Xiang
Methods in Molecular Medicine|June 22, 2005
Dendritic cell/myeloma hybrid vaccineDajing Xia, Tim Chan, Jim Xiang
Journal of Leukocyte Biology|July 13, 2007
Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memorySiguo Hao, Jinying Yuan, Jim Xiang
Journal of Immunology (Baltimore, Md. : 1950)|August 22, 2006
CD8+ cytotoxic T-APC stimulate central memory CD8+ T cell responses via acquired peptide-MHC class I complexes and CD80 costimulation, and IL-2 secretionDajing Xia, Siguo Hao, Jim Xiang
Cancer Biotherapy & Radiopharmaceuticals|August 3, 2004
Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunityDajing Xia, Fang Li, Jim Xiang
Cancer Biotherapy & Radiopharmaceuticals|March 28, 2002
Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cellsYongqing Liu, Mabood Qureshi, Jim Xiang
Oncotargets and Therapy|November 10, 2018
Novel EXO-T vaccine using polyclonal CD4<sup>+</sup> T cells armed with HER2-specific exosomes for HER2-positive breast cancerRong Li, Rajni Chibbar, Jim Xiang
Breast Cancer (Tokyo, Japan)|January 31, 2015
HER2-directed therapy: current treatment options for HER2-positive breast cancerShahid Ahmed, Amer Sami, Jim Xiang
Immunotargets and Therapy|July 11, 2018
Multiple effects of CD40-CD40L axis in immunity against infection and cancerAnjuman Ara, Khawaja Ashfaque Ahmed, Jim Xiang
Pageof 17